Higher dose of bioengineered vaccine boosts survival in cancer study

11/6/2011 | Reuters

Patients with metastatic liver cancer who received a higher dose of Jennerex's JX-594, a vaccine candidate derived from smallpox virus, had median survival of 13.8 months, compared with 6.7 months for a lower-dose group, a Phase II trial found. Jennerex began enrollment in a another midstage study evaluating JX-594 in patients who no longer respond to standard treatment Nexavar, by Onyx Pharmaceuticals and Bayer HealthCare Pharmaceuticals. A Phase III comparative test is planned for next year.

View Full Article in:


Published in Brief: